9018 related articles for article (PubMed ID: 21969168)
1. CDH22 expression is reduced in metastatic melanoma.
Piche B; Khosravi S; Martinka M; Ho V; Li G
Am J Cancer Res; 2011; 1(2):233-239. PubMed ID: 21969168
[TBL] [Abstract][Full Text] [Related]
2.
Martín-Sánchez E; Mendaza S; Ulazia-Garmendia A; Monreal-Santesteban I; Córdoba A; Vicente-García F; Blanco-Luquin I; De La Cruz S; Aramendia A; Guerrero-Setas D
Clin Epigenetics; 2017; 9():7. PubMed ID: 28149335
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions.
Ivan D; Diwan AH; Esteva FJ; Prieto VG
Mod Pathol; 2004 Jul; 17(7):811-8. PubMed ID: 15154004
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
PLoS One; 2011 Feb; 6(2):e17578. PubMed ID: 21386910
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.
Chen PL; Chen WS; Li J; Lind AC; Lu D
Mod Pathol; 2013 Jan; 26(1):44-53. PubMed ID: 22899289
[TBL] [Abstract][Full Text] [Related]
7. C-terminal tensin-like protein is a novel prognostic marker for primary melanoma patients.
Sjoestroem C; Khosravi S; Zhang G; Martinka M; Li G
PLoS One; 2013; 8(11):e80492. PubMed ID: 24244691
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.
Slipicevic A; Holm R; Emilsen E; Ree Rosnes AK; Welch DR; Mælandsmo GM; Flørenes VA
BMC Cancer; 2012 Feb; 12():73. PubMed ID: 22356677
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
10. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Kiszner G; Wichmann B; Nemeth IB; Varga E; Meggyeshazi N; Teleki I; Balla P; Maros ME; Penksza K; Krenacs T
Virchows Arch; 2014 May; 464(5):603-12. PubMed ID: 24682564
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
13. Loss of SNF5 expression correlates with poor patient survival in melanoma.
Lin H; Wong RP; Martinka M; Li G
Clin Cancer Res; 2009 Oct; 15(20):6404-11. PubMed ID: 19808872
[TBL] [Abstract][Full Text] [Related]
14. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
15. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
16. DEK expression in melanocytic lesions.
Kappes F; Khodadoust MS; Yu L; Kim DS; Fullen DR; Markovitz DM; Ma L
Hum Pathol; 2011 Jul; 42(7):932-8. PubMed ID: 21316078
[TBL] [Abstract][Full Text] [Related]
17. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
[TBL] [Abstract][Full Text] [Related]
19. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of p53 is a late event in the development of malignant melanoma.
Lassam NJ; From L; Kahn HJ
Cancer Res; 1993 May; 53(10 Suppl):2235-8. PubMed ID: 8485708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
